From Pharmacokinetics, Dynamics and Metabolism-New Chemical Entities, Pfizer Inc., Groton, Connecticut 06340.
J Biol Chem. 2014 Feb 21;289(8):4562-70. doi: 10.1074/jbc.R113.529156. Epub 2013 Dec 20.
A need for better clinical outcomes has heightened interest in the use of physiologically relevant human cells in the drug discovery process. Patient-specific human induced pluripotent stem cells may offer a relevant, robust, scalable, and cost-effective model of human disease physiology. Small molecule high throughput screening in human induced pluripotent stem cell-derived cells with the intent of identifying novel therapeutic compounds is starting to influence the drug discovery process; however, the use of these cells presents many high throughput screening development challenges. This technology has the potential to transform the way drug discovery is performed.
人们对更好的临床结果的需求，使得人们对在药物发现过程中使用与生理相关的人类细胞产生了浓厚的兴趣。患者特异性的人诱导多能干细胞可能提供一种相关的、强大的、可扩展的和具有成本效益的人类疾病生理学模型。小分子高通量筛选人诱导多能干细胞衍生细胞，旨在鉴定新的治疗化合物，这开始影响药物发现过程；然而，这些细胞的使用也带来了许多高通量筛选开发的挑战。这项技术有可能改变药物发现的方式。
